Emerging therapies for cystic fibrosis lung disease

Expert Opinion on Emerging Drugs

Volumn 15, Issue 4, 2010, Pages 653-659

  Grasemann, Hartmut ^a,b   Ratjen, Felix ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

CFTR pharmacotherapy; chloride secretion; clinical trials; cystic fibrosis; osmotic therapy

Indexed keywords

ATALUREN; CHLORIDE CHANNEL; DENUFOSOL; DURAMYCIN; GS 9411; LANCOVUTIDE; MANNITOL; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 770; VX 809;

CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG MECHANISM; DRUG RESEARCH; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; ION CHANNELS;

EID: 78649480526     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.517746     Document Type: Review

References (58)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73 (Pubitemid 19231814)
2. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-65 (Pubitemid 19231813)
3. The Cystic Fibrosis Genetic Analysis Consortium. Available from: http://www.genet.sickkids.on. ca/cftr
4. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9
5. Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007;13:541-6
6. Schwiebert EM, Morales MM, Devidas S, et al. Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 1998;95:2674-89
7. Quinton PM. The neglected ion: HCO3-. Nat Med 2001;7:292-3
8. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008;77:701-26
9. Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006;127:803-15
10. Reddy MM, Light MJ, Quinton PM. Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl-channel function. Nature 1999;402:301-4
11. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15
12. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71
13. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006;354:291-3
14. Elkins M, Robinson M, Rose B, et al. National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40
15. Robinson M, Hemming A, Regnis J, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3
16. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50
17. Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010;65:379-83
18. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007;42:471-6
19. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-96
20. Bilton D, Robinson P, Cooper P, et al. Phase III study of inhaled dry powder mannitol (BronchitolTM) in cystic fibrosis - results from the 6 month open label phase. Am J Respir Crit Care Med 2010;181: A2338
21. Available from: http://clinicaltrials.gov/ct2/show/NCT00446680
22. Bartholdson SJ, Brown AR, Mewburn BR, et al. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology 2008;154:2513-21
23. Chan HC, Goldstein J, Nelson DJ. Alternate pathways for chloride conductance activation in normal and cystic fibrosis airway epithelial cells. Am J Physiol 1992;262: C1273-83
24. Guilbault C, Saeed Z, Downey G, Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007;36:1-7
25. Zeitlin P, Boyle M, Guggino W. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2005;25:143-9
26. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007;131:1461-6
27. Tarran R, Button B, Picher M, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005;280:35751-9
28. Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev 2006;7(Suppl 1): S151-3
29. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533-8
30. Kellerman D, Rossi Mospan A, Engels J, et al. Denufosol: a review of studies with inhaled P2Y (2) agonists that led to Phase 3. Pulm Pharmacol Ther 2008;21:600-7
31. Accurso F. The Tiger-1 clinical trial on denufosol in cystic fibrosis. Pediatr Pulmonol 2008; (Suppl 31):191A
32. Available from: http://clinicaltrials.gov/ct2/show/NCT00625612
33. Mall M, Grubb B, Harkema J, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-93
34. Burrows E, Southern K, Noone P. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2006;3: CD005087
35. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC- overexpressing Mice. Am J Respir Crit Care Med 2008;178:1245-56
36. Hirsh A, Molino B, Zhang J, et al. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006;49:4098-115
37. Available from: http://clinicaltrials.gov/ct2/results?term=GS-9411+
38. Li C, Ramjeesingh M, Reyes E, et al. The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR. Nat Genet 1993;3:311-16
39. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular traffic and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-34
40. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992;68:809-18
41. Okiyoneda T, Lukacs GL. Cell surface dynamics of CFTR: the ins and outs. Biochim Biophys Acta 2007;1773:476-9
42. Kerem E. Mutation specific therapy in CF. Paediatr Respir Rev 2006;7: S166-9
43. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001;281: C1734-42
44. Van Goor F, Straley K, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Cell Physiol 2006;290: L1117-30
45. Clancy JP, Spencer-Green G; for the VX-809-101 Study Group. Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. J Cyst Fibros 2010;9(Suppl 1): S20
46. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-30
47. Available from: http://www.cff.org/research/ClinicalResearch/FAQs/VX-770
48. Available from: http://clinicaltrials.gov/ct2/show/study?intr=%22VX-770% 22&rank=8
49. Available from: http://clinicaltrials.gov/ct2/show/NCT00953706
50. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-41
51. Welch E, Barton E, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
52. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-44
53. Available from: http://clinicaltrials.gov/ct2/show/NCT00803205?intr= %22PTC124%22&rank=2
54. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007;5:5
55. Available from: http://clinicaltrials.gov/ct2/results?term=Ataluren+
56. Griesenbach U, Alton EW. Cystic fibrosis gene therapy: successes, failures and hopes for the future. Expert Rev Respir Med 2009;3(4):363-71
57. Alton E, Davies J, Geddes D. Biomarkers for cystic fibrosis: are we progressing? Am J Respir Crit Care Med 2007;175:750-1
58. Available from: http://www.cff.org/research/DrugDevelopmentPipeline